Home > Riviste > Minerva Endocrinology > Fascicoli precedenti > Articles online first > Minerva Endocrinology 2022 Feb 01

ULTIMO FASCICOLO
 

JOURNAL TOOLS

Opzioni di pubblicazione
eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

 

Minerva Endocrinology 2022 Feb 01

DOI: 10.23736/S2724-6507.22.03646-6

Copyright © 2022 EDIZIONI MINERVA MEDICA

lingua: Inglese

A clinical and in-silico study of MicroRNA-21 and growth differentiation factor-15 expression in pre-diabetes, type 2 diabetes and diabetic nephropathy

Riddhi G. AGARWAL 1, Manoj KHOKHAR 1, Purvi PUROHIT 1 , Anupama MODI 1, Nitin K. BAJPAI 2, Gopal K. BOHRA 3, Mahendra K. GARG 3, Praveen SHARMA 1

1 Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, India; 2 Department of Nephrology, All India Institute of Medical Sciences, Jodhpur, India; 3 Department of General Medicine, All India Institute of Medical Sciences, Jodhpur, India


PDF


BACKGROUND: Diabetic Nephropathy (DN), a microvascular complication associated with long-standing diabetes, is a major cause of the end-stage renal disease (ESRD). Our in-silico analysis indicates several enrichment analyses involved in glucose metabolism to be affected by GDF15 transcription factors.
METHODS: In-silico analysis was used to identify GDF15 and Insulin related protein-protein interaction (PPI) network and a common set of GDF15 regulating transcription factors by various databases. Common targeting miRNA of GDF15 regulating transcription factors were investigated in miRNet and TargetScan. Further, healthy controls (n=30) and patients with pre-Type-2 Diabetes mellitus (Pre-diabetes) (n=30), T2DM (n=30) and DN (n=30) were included for analysis of routine biochemical tests, serum GDF15 levels by ELISA and to evaluate the Fold change expression (FCE) of circulating hsa-miR-21 by RT-PCR.
RESULTS: MicroRNA-21 was found to directly target GDF15 downregulating transcription factors KLF4, TP53, and CEBPB. A significant difference in the levels of serum GDF15 was observed in Pre-diabetes (708.56 ±76.37), T2DM (1528.87 ±140.75) and DN patients (10-fold higher; 5507.90 ±503.88) when compared to healthy controls (567.36 ±69.99). The FCE of circulating hsa-miR-21 was 6.19 (Pre-diabetes), 8.22 (T2DM), 9.19 (DN), folds higher in cases as compared to controls, reflecting an increasing trend and several folds higher levels of hsa-miR-21 in patients.
CONCLUSIONS: We suggest the potential of serum GDF15 and circulating-hsa-miR-21 to serve as clinically important biomarkers and therapeutic targets for controlling advancement of diabetes to DN.


KEY WORDS: Biomarkers; Diabetic nephropathy; MicroRNA; Type 2 diabetes mellitus; Transforming growth factor-β

inizio pagina